Osetra syrup contains ondansetron which is a serotonin 5-HT3 receptor antagonist which is used to prevent nausea and vomiting in severe conditions like cancer chemotherapy, radiation therapy or surgery. It blocks the actions of chemicals present in the body which causes triggering of nausea and vomiting.
- Prevention of nausea and vomiting in severe cases of highly emetogenic cancer chemotherapy
- In repeated courses of emetogenic cancer chemotherapy
- Nausea and vomiting associated with radiotherapy in patient with total body irradiation
Ondansetron – 2 mg/5 ml
It is a selective serotonin 5-HT3 receptor antagonist. The drug produces its antiemetic action by inhibition of 5-HT3 receptor present centrally or peripherally. This causes inhibition of vomiting centre, indirectly at the area postrema level and directly by inhibiting the serotonin activity in area postrema and chemoreceptor trigger zone (CTZ).
After oral administration the drug is absorbed from GI tract. The drug follows first pass metabolism.
After oral administration the drug is well distributed in the body. The drug is metabolized by hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation.
The excretion of the drug is through urine.
- Use of apomorphine with ondansetron can cause loss of consciousness and hypotension
- Patients known to have hypersensitivity to the drug.
- It can cause increase in peristaltic movement, not be used instead of nasogastric suction.
- Can cause gastric distension
- Not to be used in nursing mothers